Acadia to present pipeline updates at Parkinson’s congress

SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a pharmaceutical company with over $1 billion in annual revenue and a market capitalization of $3.58 billion, will showcase three presentations at the International Congress of Parkinson’s Disease and Movement Disorders taking place October 5-9, 2025, in Honolulu, Hawaii, according to a press release statement. InvestingPro analysis shows the company maintains strong financial health with a "GREAT" overall score, supported by a robust 60% gross profit margin.

The presentations include one late-breaker oral platform presentation on ACP-711, an investigational drug for essential tremor, providing preclinical efficacy, safety, and mechanism of action findings. The company will also present two posters: one outlining the Phase 2 study design for ACP-204 in adults with Lewy body dementia psychosis, and another featuring a post-hoc analysis of clinical trial data on NUPLAZID (pimavanserin) in Parkinson’s disease psychosis. According to InvestingPro data, Acadia’s strong research pipeline is backed by a healthy balance sheet with more cash than debt, positioning it well for continued drug development.

The late-breaker presentation on ACP-711, described as a GABAA subunit α3 selective modulator, is scheduled for Wednesday, October 8. The poster on the ACP-204 study design and the analysis of pimavanserin response related to illness duration will both be presented on Tuesday, October 7.

NUPLAZID is Acadia’s FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. The drug carries a boxed warning regarding increased mortality risk in elderly patients with dementia-related psychosis and is not approved for dementia patients unless their hallucinations and delusions are specifically related to Parkinson’s disease.

Acadia Pharmaceuticals focuses on developing treatments for neurological and rare diseases. The company’s commercial portfolio includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.

In other recent news, Acadia Pharmaceuticals reported that its Phase 3 COMPASS trial for the drug candidate ACP-101 did not meet the primary endpoint in treating Prader-Willi Syndrome. This development has led several analyst firms to adjust their price targets for the company. BMO Capital maintained its Outperform rating with a price target of $28.00, despite the trial’s failure. TD Cowen lowered its price target from $39.00 to $35.00 while maintaining a Buy rating. Oppenheimer also adjusted its price target, decreasing it from $22.00 to $21.00, while keeping a Perform rating. Additionally, BofA Securities has maintained its Neutral rating with a $27.00 price target. The trial’s outcome has prompted a reassessment of the company’s prospects by these analyst firms. These developments highlight the challenges Acadia faces in advancing its drug pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.